Rigorously tested and continuously validated in practice, Cytel software is used at thousands of pharmaceutical, biotech, medical device companies, and leading independent research institutes.
Cytel’s cutting-edge trial design and implementation expertise, with a specialty in adaptive trials, is helping sponsor companies of all sizes to increase success rates in clinical development.
Adaptive Dose-Escalation and Trial Prediction in East® v6.3
New dose-escalation designs, gatekeeping procedures for multiple endpoints, and interim analysis trial prediction tools, continue East® software’s twenty year tradition of reliable innovation.
Cytel Adaptive Trial Experts at ISCB 2014, Vienna
Cytel statisticians contribute expert talks, panel appearances, and an adaptive trials workshop at this year’s Intl. Society for Clinical Biostatistics conference (ISCB) conference August 24 – 28.
Register for EUGM 2014: East® User Group Meeting
Our annual EUGM begins with East software training on Oct 21. The Oct 22 adaptive trial innovations Open Meeting features guests LJ Wei, Michael Proshan, and Ashwin Gollerkeri.
What Clients Say
Simona Skerjanec, VP Medical Science
The Medicines Company
Steven B. Ketchum, VP Research and Development
Joe Heyes, VP
Early Stage Biostatistics Merck
Dr. Scott Harris, CMO
Dr. Patrice Rioux, VP, CMO
Sylvain Nicolas, Global Head Biostatistics Phase 1 Studies